What the research found
This isn't a research briefing—it's a regulatory history. Between 2015 and 2022, enclomiphene citrate was evaluated by the FDA on four separate occasions and rejected each time. The drug never received formal FDA approval. Notably, its advisory committee meeting was cancelled five days before it was scheduled to convene in 2015, so a panel vote on approval never actually occurred. The FDA's stated concerns shifted across reviews: from assay validation problems, to inadequate study design relative to evolving scientific standards, to a December 2016 advisory panel vote where committee members concluded that raising testosterone and preserving sperm count alone were insufficient to establish clinical benefit in obese men with secondary hypogonadism—the narrow population Repros had originally sought to treat.
What makes this story relevant to MyKine users is the paradoxical regulatory status: because enclomiphene was never approved, it was never scheduled as a controlled substance. Testosterone is Schedule III, which restricts telehealth dispensing under the Ryan Haight Act. Enclomiphene operates in a legal grey area where compounding pharmacies can legally provide it across all 50 states, whereas FDA-approved TRT is accessible via telehealth in only 35 states as of early 2026.
Why it matters for you
If you're considering alternatives to conventional TRT—perhaps due to geographic restrictions, regulatory barriers, or desire to preserve testicular function and fertility—understanding enclomiphene's regulatory standing is essential context. The drug exists in the market not because regulators endorsed it, but because they never formally banned it. That's materially different from approval.
For users tracking biomarkers like testosterone, LH, FSH, and sperm concentration, enclomiphene's mechanism (SERM activity) differs fundamentally from exogenous testosterone replacement. Whether it achieves the same biomarker targets or clinical outcomes in your specific situation remains unresolved in the regulatory record. The December 2016 advisory panel's judgment—that testosterone normalisation plus preserved sperm count wasn't sufficient evidence of benefit—is worth considering if fertility or testicular function preservation is part of your health goals.
The availability-versus-approval gap also has practical implications: widespread access doesn't indicate safety or efficacy at population scale, only that regulatory pathways closed before a scheduling decision was made.
Caveats
- No clinical trial data presented here; this is a regulatory timeline
- The original indication was narrowly defined (obese men under 60 with normal sperm counts)—generalisability to other populations unknown
- No long-term safety or efficacy data provided; approval was declined before Phase 3 completion
- The advisory panel's reasoning was specific to the claimed clinical benefit in one subpopulation; it did not assess other uses
- Compounding availability reflects regulatory absence, not affirmative safety clearance